![Kyri van Hoose](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kyri van Hoose
Directeur Financier/CFO chez
DERMATA THERAPEUTICS, INC.
Fortune : 168 246 $ au 30/06/2026
Profil
Kyri K.
van Hoose is Vice President-Accounting at Turning Point Therapeutics, Inc. since 2021.
Mr. van Hoose is Chief Financial Officer & Senior Vice President at Dermata Therapeutics, Inc. since 2021.
Former roles include Corporate Controller & Senior Director-Finance at ACADIA Pharmaceuticals, Inc. from 2005 to 2016, Head-Finance at Avelas Biosciences, Inc. from 2017 to 2019, Head-Finance at Curzion Pharmaceuticals, Inc. from 2019 to 2020, and Chief Financial Officer at TEGA Therapeutics, Inc. from 2020 to 2021.
Education includes an undergraduate degree from the University of Southern California in 2000 and an MBA from the University of California, Irvine in 2005.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 27/05/2026 | 130 423 ( 4,6 % ) | 168 246 $ | 30/06/2026 |
Postes actifs de Kyri van Hoose
| Sociétés | Poste | Début |
|---|---|---|
| TURG POIN | Comptroller/Controller/Auditor | 05/05/2021 |
| DERMATA THERAPEUTICS, INC. | Directeur Financier/CFO | 01/09/2021 |
Anciens postes connus de Kyri van Hoose
| Sociétés | Poste | Fin |
|---|---|---|
TEGA Therapeutics, Inc.
 TEGA Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics and lifesaving treatments | Directeur Financier/CFO | 30/04/2021 |
Curzion Pharmaceuticals, Inc.
 Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Corporate Officer/Principal | 01/04/2020 |
Avelas Biosciences, Inc.
 Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Develops integrated suite of therapeutic and imaging agents for treatment of cancer | Directeur Financier/CFO | 01/07/2019 |
| ACADIA PHARMACEUTICALS INC. | Comptroller/Controller/Auditor | 01/02/2016 |
Formation de Kyri van Hoose
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
84
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage structure-based drug design company for discovery and development of precision medicines for cancer and other diseases | Health Technology |
Dermata Therapeutics, Inc.
 Dermata Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which focusing on the treatment of medical and aesthetic skin conditions | Health Technology |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Develops integrated suite of therapeutic and imaging agents for treatment of cancer | Health Services |
Curzion Pharmaceuticals, Inc.
Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
TEGA Therapeutics, Inc.
TEGA Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics and lifesaving treatments | Health Technology |
Choisissez Zonebourse 
